X4 Pharmaceuticals
XFOR
93 hedge funds and large institutions have $23.6M invested in X4 Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 10 closing their positions.
552% more call options, than puts
Call options by funds: $202K | Put options by funds: $31K
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
4% more funds holding
Funds holding: 89 → 93 (+4)
0.06% less ownership
Funds ownership: 1.95% → 1.89% (-0.06%)
68% less capital invested
Capital invested by funds: $73.2M → $23.6M (-$49.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.89M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$947K |
| 3 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$291K |
| 4 |
BlackRock
New York
|
+$170K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$56.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
-$1.09M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$934K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$485K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$465K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$287K |
XFOR Hedge Fund Activity: Q1 2025 in Review
93 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2025, worth a combined $23.6M — down 68% from $73.2M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new XFOR positions and 10 closed out — a net gain of 5 holders — while 28 added to existing stakes and 22 trimmed.
The largest buyer was UBS Group, adding an estimated $1.89M. The largest seller was Axa, cutting an estimated $1.09M.
- 93 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2025, up from 89 in Q4 2024.
- Funds reported $23.6M of X4 Pharmaceuticals stock for Q1 2025, down 68% quarter-over-quarter.
- 15 funds opened new X4 Pharmaceuticals positions in Q1 2025 and 10 closed out, a net change of +5 holders.
- The largest X4 Pharmaceuticals buyer in Q1 2025 was UBS Group, an estimated $1.89M added.
- The largest X4 Pharmaceuticals seller in Q1 2025 was Axa, an estimated $1.09M sold.
Based on aggregated 13F filings for Q1 2025.